Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

(2014) M. Weisser et al.   BLOOD

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

(2013) A. Dufour et al.   BLOOD

Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

(2012) Kirsten Fischer et al.   JOURNAL OF CLINICAL ONCOLOGY

High expression ofMZB1predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signature

(2012) Tobias Herold et al.   LEUKEMIA & LYMPHOMA

An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia

(2011) T Herold et al.   LEUKEMIA

Prognostic Markers and Stratification of Chronic Lymphocytic Leukemia

(2011) R. R. Furman   Hematology-American Society of Hematology Education Program

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

(2010) Tadeusz Robak et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Inpp5f Is a Polyphosphoinositide Phosphatase That Regulates Cardiac Hypertrophic Responsiveness

(2009) Wenting Zhu et al.   CIRCULATION RESEARCH

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

(2008) C. Pepper et al.   BLOOD

The NF- B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

(2008) S. Hewamana et al.   BLOOD

Bcl-2-family proteins and hematologic malignancies: history and future prospects

(2008) J. C. Reed   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

The Novel Nuclear Factor- B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine

(2008) S. Hewamana et al.   CLINICAL CANCER RESEARCH

BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism

(2007) A. Majid et al.   BLOOD

PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity

(2007) Kewei Ma et al.   CELLULAR SIGNALLING